These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26243073)

  • 1. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success.
    Sugino H; Watanabe A; Amada N; Yamamoto M; Ohgi Y; Kostic D; Sanchez R
    Clin Ther; 2015 Aug; 37(8):1632-42. PubMed ID: 26243073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
    Broich K
    Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of the task force on designing clinical trials in early (predementia) AD.
    Aisen PS; Andrieu S; Sampaio C; Carrillo M; Khachaturian ZS; Dubois B; Feldman HH; Petersen RC; Siemers E; Doody RS; Hendrix SB; Grundman M; Schneider LS; Schindler RJ; Salmon E; Potter WZ; Thomas RG; Salmon D; Donohue M; Bednar MM; Touchon J; Vellas B
    Neurology; 2011 Jan; 76(3):280-6. PubMed ID: 21178097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer's Disease in Japan.
    Moritoyo T
    Clin Ther; 2015 Aug; 37(8):1622-6. PubMed ID: 26342202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study design considerations: conducting global clinical trials in early Alzheimer's disease.
    Schindler RJ
    J Nutr Health Aging; 2010 Apr; 14(4):312-4. PubMed ID: 20306004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and evolving treatment strategies for the Alzheimer disease continuum.
    Marasco RA
    Am J Manag Care; 2020 Aug; 26(8 Suppl):S167-S176. PubMed ID: 32840330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
    Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
    Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.
    Cummings JL; Tong G; Ballard C
    J Alzheimers Dis; 2019; 67(3):779-794. PubMed ID: 30689575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery strategies for Alzheimer's disease treatment.
    Di Stefano A; Iannitelli A; Laserra S; Sozio P
    Expert Opin Drug Deliv; 2011 May; 8(5):581-603. PubMed ID: 21391862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development in Alzheimer's disease: the path to 2025.
    Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
    Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Alzheimer's disease therapeutics.
    Rafii MS
    J Alzheimers Dis; 2014; 42 Suppl 4():S545-9. PubMed ID: 25079804
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.